View by Specialty

Trending

PC0225Bischoff-Ferrari_Graphic_01_WEB
February 13, 2025
2 min read
Save

Daily omega-3 slows biological aging by almost 4 months

Viral Hepatitis News

SPONSORED CONTENT
January 31, 2025
5 min read
Save
Viral hepatitis elimination requires equitable public health approach

Viral hepatitis elimination requires equitable public health approach

Viral hepatitis is a major danger to public health. According to WHO’s 2024 Global Hepatitis Report, viral hepatitis deaths increased from 1.1 million in 2019 to 1.3 million in 2022, rates now similar to tuberculosis.

SPONSORED CONTENT
January 28, 2025
3 min read
Save

Chronic HBV treatment with xalnesiran plus immunomodulator confers highest HBsAg loss

Chronic HBV treatment with xalnesiran plus immunomodulator confers highest HBsAg loss

Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study published in The New England Journal of Medicine.

SPONSORED CONTENT
December 23, 2024
1 min read
Save

CDC: Heplisav-B joins recommended HBV vaccine options for pregnant patients

CDC: Heplisav-B joins recommended HBV vaccine options for pregnant patients

Data from a postlicensure study support the CDC’s recommendation that Heplisav-B can now be administered to pregnant persons needing hepatitis B vaccination, as its use did not appear to increase risk for major birth defects or miscarriage.

Trending

PC0225Bischoff-Ferrari_Graphic_01_WEB
February 13, 2025
2 min read
Save

Daily omega-3 slows biological aging by almost 4 months

SPONSORED CONTENT
December 06, 2024
2 min read
Save

HCC incidence nearly 5-times higher among HBV, HDV coinfected patients with cirrhosis

HCC incidence nearly 5-times higher among HBV, HDV coinfected patients with cirrhosis

Incidence of hepatocellular carcinoma was significantly higher among cirrhotic patients coinfected with hepatitis B and D viruses compared with those with HBV alone, with researchers suggesting HDV “plays a direct role” in HCC occurrence.

SPONSORED CONTENT
December 05, 2024
2 min read
Save

‘Only one in six’ veterans with chronic HBV finish HDV testing despite severe disease risk

‘Only one in six’ veterans with chronic HBV finish HDV testing despite severe disease risk

Among veterans with chronic hepatitis B virus infection, rates of hepatitis D virus testing were low and those with concurrent infection were at greater risk for cirrhosis and hepatic decompensation, according to study results.

SPONSORED CONTENT
November 21, 2024
2 min read
Save

Combination PEG-INF a-2b therapy achieves higher HBsAg loss in HBV-infected children

Combination PEG-INF a-2b therapy achieves higher HBsAg loss in HBV-infected children

SAN DIEGO — Combination therapy with peginterferon alfa-2b and nucleos(t)ide analogues resulted in significantly higher hepatitis B surface antigen loss vs. monotherapy in children with HBV, especially among those aged younger than 7 years.

SPONSORED CONTENT
November 20, 2024
4 min watch
Save

VIDEO: Combination tobevibart, elebsiran induces ‘rapid virologic suppression’ in HDV

VIDEO: Combination tobevibart, elebsiran induces ‘rapid virologic suppression’ in HDV

SAN DIEGO — Combination tobevibart and elebsiran led to “profound and rapid virologic suppression” as well as normalization of alanine aminotransferase at week 24 in chronic hepatitis D virus infection, according to preliminary data.

SPONSORED CONTENT
November 19, 2024
3 min watch
Save

VIDEO: HBsAg loss with tobevibart, elebsiran combination ‘highly promising’ in chronic HBV

VIDEO: HBsAg loss with tobevibart, elebsiran combination ‘highly promising’ in chronic HBV

SAN DIEGO — Treatment with combination tobevibart and elebsiran led to hepatitis B surface antigen loss among 39% of patients with chronic HBV and low baseline HBsAg, which rose to 46% by adding pegylated interferon-alfa, data showed.

SPONSORED CONTENT
November 17, 2024
2 min read
Save

Resuming antiviral therapy after withdrawal does not affect HBsAG seroclearance in HBV

Resuming antiviral therapy after withdrawal does not affect HBsAG seroclearance in HBV

SAN DIEGO — Retreatment with nucleos(t)ide analogue therapy for relapse after withdrawal did not affect hepatitis B surface antigen seroclearance among patients with chronic HBV infection, according to a researcher at The Liver Meeting.

SPONSORED CONTENT
November 12, 2024
3 min read
Save

‘Change the HDV narrative’: A call to heighten awareness, prioritize early detection

‘Change the HDV narrative’: A call to heighten awareness, prioritize early detection

As you read these words, you may be learning for the first time about hepatitis delta virus — a lesser-known type of hepatitis that is potentially life-threatening.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails